Increased serum oestrone and oestradiol following spironolactone administration in hypertensive men
| Autor: | Yuichi Yamamura, Keizo Noma, Akihiko Miyatake, Yasuhiko Morimoto, Kiyohide Nakao |
|---|---|
| Rok vydání: | 1978 |
| Předmět: |
Adult
Male endocrine system medicine.medical_specialty Estrone Endocrinology Diabetes and Metabolism Sexual Behavior Spironolactone Essential hypertension Serum prolactin chemistry.chemical_compound Basal (phylogenetics) Endocrinology Internal medicine Medicine Humans Testosterone Estradiol business.industry Middle Aged medicine.disease Prolactin chemistry Male patient Hypertension Gynecomastia business Idiopathic hyperaldosteronism hormones hormone substitutes and hormone antagonists |
| Zdroj: | Clinical endocrinology. 9(6) |
| ISSN: | 0300-0664 |
| Popis: | SUMMARY The present study was undertaken to evaluate long-term effects of spironolactone on basal serum oestrone, oestradiol, testosterone, LH and prolactin concentrations in hypertensive male patients. Serum prolactin response to TRH was also evaluated. Patients were divided into two groups: a conventional-dosage group, consisting of six males with essential hypertension who took 75 to 150 mg of spironolactone daily for 12 weeks, and a high-dosage group, consisting of two males with idiopathic hyperaldosteronism who took 300 mg of spironolactone daily for more than 40 weeks. In the conventional-dosage group, serum oestrone concentrations significantly increased (P > 0.01) at 12 weeks, serum oestradiol concentrations gradually increased throughout the study period, however, the increments were not statistically significant (P > 0.2). Basal serum testosterone, LH and prolactin concentrations were not significantly changed throughout the study period. Enhancement of serum prolactin response to TRH was not found in any of the patients in the conventional-dosage group. In the high-dosage group, serum oestrone maintained high levels from the beginning of this study, and serum oestradiol concentrations increased with the development of gynaecomastia. Serum testosterone, LH and prolactin concentrations did not show any definite change throughout the study period. Thus, long-term spironolactone treatment increased the serum levels of oestrone and oestradiol in hypertensive men followed by the development of gynaecomastia. The elevations in circulating oestrogens could well explain the oestrogenic side-effects of spironolactone treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text